Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

Apoptosis

Volumn 22, Issue 7, 2017, Pages 898-919

  Rathore, Rama ^a   McCallum, Jennifer E ^b   Varghese, Elizabeth ^b   Florea, Ana Maria ^c   Büsselberg, Dietrich ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chemotherapy resistance; Combination therapy; Extrinsic apoptotic pathway; Inhibitors of apoptosis proteins; Intrinsic apoptotic pathway

Indexed keywords

DOXORUBICIN; DROZITUMAB; HUMAN MONOCLONAL ANTIBODY; INHIBITORS OF APOPTOSIS PROTEIN 1; INHIBITORS OF APOPTOSIS PROTEIN 2; PEPTIDOMIMETIC AGENT; PROTEIN; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BIRC5 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; TNFSF10 PROTEIN, HUMAN; XIAP PROTEIN, HUMAN;

APOPTOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL SURVIVAL; DRUG ANTAGONISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NEOPLASM; PATHOLOGY;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 85018523450     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-017-1375-1     Document Type: Review

References (188)

1. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116(2):205–219
2. Ghobrial IM, Witzig TE, Adjei AA (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55(3):178–194
3. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092):437–443. doi:10.1038/nature04871
4. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E (2016) PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34(9):953–962. doi:10.1200/JCO.2015.64.8824
5. Sears CR, Cooney SA, Chin-Sinex H, Mendonca MS, Turchi JJ (2016) DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Repair 40:35–46. doi:10.1016/j.dnarep.2016.02.004
6. Su Z, Yang Z, Xie L, DeWitt JP, Chen Y (2016) Cancer therapy in the necroptosis era. Cell Death Differ 23(5):748–756. doi:10.1038/cdd.2016.8
7. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O’Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521(7553):489–494. doi:10.1038/nature14410
8. Coley HM (2010) Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods in molecular biology 596:341–358. doi:10.1007/978-1-60761-416-6_15
9. Hersey P, Zhang XD (2003) Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 196(1):9–18. doi:10.1002/jcp.10256
10. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10(1):172–180. doi:10.1097/JTO.0000000000000383
11. Hunter AM, LaCasse EC, Korneluk RG (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9):1543–1568. doi:10.1007/s10495-007-0087-3
12. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316–323. doi:10.1038/nature03097
13. Stojanovska V, Sakkal S, Nurgali K (2015) Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol 308(4):G223–G232. doi:10.1152/ajpgi.00212.2014
14. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S (2009) Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9:125. doi:10.1186/1471-2407-9-125
15. Fulda S (2014) Molecular pathways: targeting death receptors and smac mimetics. Clin Cancer Res 20(15):3915–3920. doi:10.1158/1078-0432.CCR-13-2376
16. Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25(34):4798–4811. doi:10.1038/sj.onc.1209608
17. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH (2013) Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 14:32. doi:10.1186/1471-2121-14-32
18. Luthi AU, Martin SJ (2007) The CASBAH: a searchable database of caspase substrates. Cell Death Differ 14:641–650
19. Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J Cell Sci 118(Pt 2):265–267. doi:10.1242/jcs.01610
20. Suzuki A, Obata S, Hayashida M, Kawano H, Nakano T, Shiraki K (2001) SADS: a new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma. Nat Med 7(1):88–93. doi:10.1038/83401
21. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400(6747):886–891. doi:10.1038/23730
22. Lopez J, Tait SW (2015) Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 112(6):957–962. doi:10.1038/bjc.2015.85
23. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21(50):7611–7618. doi:10.1038/sj.onc.1206004
24. Volkmann N, Marassi FM, Newmeyer DD, Hanein D (2014) The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ 21(2):206–215. doi:10.1038/cdd.2013.153
25. Waterhouse NJ, Goldstein JC, von Ahsen O, Schuler M, Newmeyer DD, Green DR (2001) Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J Cell Biol 153(2):319–328
26. Shamas-Din A, Kale J, Leber B, Andrews DW (2013) Mechanisms of action of Bcl-2 family proteins. Cold Spring Harbor Perspect Biol 5(4):a008714. doi:10.1101/cshperspect.a008714
27. Petros AM, Olejniczak ET, Fesik SW (2004) Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644(2–3):83–94. doi:10.1016/j.bbamcr.2003.08.012
28. Khaled AR, Kim K, Hofmeister R, Muegge K, Durum SK (1999) Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci USA 96(25):14476–14481
29. Westphal D, Dewson G, Czabotar PE, Kluck RM (2011) Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta 1813(4):521–531. doi:10.1016/j.bbamcr.2010.12.019
30. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, Andrews DW (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135(6):1074–1084. doi:10.1016/j.cell.2008.11.010
31. Shoshan-Barmatz V, Ben-Hail D, Admoni L, Krelin Y, Tripathi SS (2015) The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochim Biophys Acta 1848(10 Pt B):2547–2575. doi:10.1016/j.bbamem.2014.10.040
32. Lauterwasser J, Todt F, Zerbes RM, Nguyen TN, Craigen W, Lazarou M, van der Laan M, Edlich F (2016) The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation. Sci Rep 6:32994. doi:10.1038/srep32994
33. Mathiasen IS, Jaattela M (2002) Triggering caspase-independent cell death to combat cancer. Trends Mol Med 8(5):212–220
34. Tait SW, Ichim G, Green DR (2014) Die another way-non-apoptotic mechanisms of cell death. J Cell Sci 127:2135–2144
35. Su Z, Yang Z, Xie L, Dewitt JP, Chen Y (2016) Cancer therapy in the necroptosis era. Cell Death Differ 23:748–756
36. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516. doi:10.1080/01926230701320337
37. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104(5):781–790
38. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. doi:10.1186/1476-4598-5-67
39. Maier JK, Balabanian S, Coffill CR, Stewart A, Pelletier L, Franks DJ, Gendron NH, MacKenzie AE (2007) Distribution of neuronal apoptosis inhibitory protein in human tissues. J Histochem Cytochem 55(9):911–923. doi:10.1369/jhc.6A7144.2007
40. Diez E, Lee SH, Gauthier S, Yaraghi Z, Tremblay M, Vidal S, Gros P (2003) Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila. Nat Genet 33(1):55–60. doi:10.1038/ng1065
41. Davoodi J, Lin L, Kelly J, Liston P, MacKenzie AE (2004) Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. J Biol Chem 279(39):40622–40628. doi:10.1074/jbc.M405963200
42. Holcik M, Thompson CS, Yaraghi Z, Lefebvre CA, MacKenzie AE, Korneluk RG (2000) The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc Natl Acad Sci USA 97(5):2286–2290. doi:10.1073/pnas.040469797
43. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G (2006) Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 37(1):78–86. doi:10.1016/j.humpath.2005.09.022
44. Hsieh WC, Chuang YT, Chiang IH, Hsu SC, Miaw SC, Lai MZ (2014) Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap−/− mice. Blood 124(18):2847–2857. doi:10.1182/blood-2014-03-564609
45. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G (2007) The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Trans Med 5:6. doi:10.1186/1479-5876-5-6
46. Hou Y, Allan LA, Clarke PR (2017) Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death. J Cell Sci 130(2):502–511. doi:10.1242/jcs.192310
47. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10(11):3737–3744. doi:10.1158/1078-0432.CCR-03-0642
48. Mufti AR, Burstein E, Duckett CS (2007) XIAP: cell death regulation meets copper homeostasis. Arch Biochem Biophys 463(2):168–174. doi:10.1016/j.abb.2007.01.033
49. Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS (2010) Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 222(2):180–190. doi:10.1002/path.2747
50. Liu J, Zhang D, Luo W, Yu Y, Yu J, Li J, Zhang X, Zhang B, Chen J, Wu XR, Rosas-Acosta G, Huang C (2011) X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J Biol Chem 286(18):15630–15640. doi:10.1074/jbc.M110.176982
51. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T (2007) Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30(4):919–925
52. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R (2000) Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 275(29):22064–22068. doi:10.1074/jbc.M910346199
53. Pluta P, Jeziorski A, Cebula-Obrzut AP, Wierzbowska A, Piekarski J, Smolewski P (2015) Expression of IAP family proteins and its clinical importance in breast cancer patients. Neoplasma 62(4):666–673. doi:10.4149/neo_2015_080
54. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115):110–114. doi:10.1038/nature05257
55. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131(4):669–681. doi:10.1016/j.cell.2007.10.030
56. Ponnelle T, Chapusot C, Martin L, Bonithon-Kopp C, Bouvier AM, Plenchette S, Rageot D, Faivre J, Solary E, Piard F (2003) Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract 199(11):723–731. doi:10.1078/0344-0338-00488
57. Kitamura H, Tsukamoto T (2008) Prognostic biomarkers of renal cell carcinoma: Recent advances. Indian J Urol 24(1):10–15. doi:10.4103/0970-1591.38596
58. Qi S, Mogi S, Tsuda H, Tanaka Y, Kozaki K, Imoto I, Inazawa J, Hasegawa S, Omura K (2008) Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg 37(11):1047–1053. doi:10.1016/j.ijom.2008.06.004
59. Samuel T, Okada K, Hyer M, Welsh K, Zapata JM, Reed JC (2005) cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 65(1):210–218
60. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, Karin M (2010) Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 11(1):70–75. doi:10.1038/ni.1819
61. Ferreira CG, van der Valk P, Span SW, Jonker JM, Postmus PE, Kruyt FA, Giaccone G (2001) Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 12(6):799–805
62. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M (2009) Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30(6):789–801. doi:10.1016/j.immuni.2009.04.011
63. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G, Leverkus M (2011) cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 43(3):449–463. doi:10.1016/j.molcel.2011.06.011
64. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2):115–130. doi:10.1016/j.ccr.2007.07.004
65. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J (2010) Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer 1(3):127–135. doi:10.1007/s12672-010-0018-6
66. Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, Roth W, Friess H, Schirmacher P (2007) Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 60(8):885–895. doi:10.1136/jcp.2006.038257
67. Jonsson G, Paulie S, Grandien A (2003) cIAP-2 block apoptotic events in bladder cancer cells. Anticancer Res 23(4):3311–3316
68. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Fama R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foa R, Gaidano G (2012) Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119(12):2854–2862. doi:10.1182/blood-2011-12-395673
69. Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS (2001) Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol 21(13):4292–4301. doi:10.1128/MCB.21.13.4292-4301.2001
70. Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S (1998) A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol 141(6):1415–1422
71. Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang X, Noda T, Tsuruo T, Naito M (2004) Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 6(9):849–860. doi:10.1038/ncb1159
72. Pohl C, Jentsch S (2008) Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell 132(5):832–845. doi:10.1016/j.cell.2008.01.012
73. Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, Valvassori L, Carinci P, Mordoh J (2006) Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 29(1):83–94
74. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A (2012) Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res 18(12):3316–3327. doi:10.1158/1078-0432.CCR-11-2232
75. Luk SU, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins CC, Gleave ME, Wang Y (2014) The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget 5(16):6896–6908. doi:10.18632/oncotarget.2229
76. Ge C, Che L, Ren J, Pandita RK, Lu J, Li K, Pandita TK, Du C (2015) BRUCE regulates DNA double-strand break response by promoting USP8 deubiquitination of BRIT1. Proc Natl Acad Sci USA 112(11):E1210–E1219. doi:10.1073/pnas.1418335112
77. Chiou SK, Jones MK, Tarnawski AS (2003) Survivin: an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci 9(4):PI25–29
78. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16:49. doi:10.1186/s12935-016-0326-1
79. Fukuda S, Mantel CR, Pelus LM (2004) Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 103(1):120–127. doi:10.1182/blood-2003-05-1756
80. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58(23):5315–5320
81. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA (2005) Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24(12):1994–2007. doi:10.1038/sj.onc.1208350
82. Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5(5):1087–1098. doi:10.1158/1535-7163.MCT-05-0375
83. Fernandez JG, Rodriguez DA, Valenzuela M, Calderon C, Urzua U, Munroe D, Rosas C, Lemus D, Diaz N, Wright MC, Leyton L, Tapia JC, Quest AF (2014) Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced beta-catenin/Tcf-Lef dependent transcription. Mol Cancer 13:209. doi:10.1186/1476-4598-13-209
84. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB (2012) Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 105(6):520–528. doi:10.1002/jso.22134
85. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM (2008) Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 173(2):575–585. doi:10.2353/ajpath.2008.071079
86. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10(21):1359–1366
87. Kim DK, Alvarado CS, Abramowsky CR, Gu L, Zhou M, Soe MM, Sullivan K, George B, Schemankewitz E, Findley HW (2005) Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol 8(6):621–629. doi:10.1007/s10024-005-4108-3
88. Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Shijubo Y, Abe S, Hirohashi Y, Torigoe T, Sato N, Watanabe N (2005) Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 48(2):217–221. doi:10.1016/j.lungcan.2004.11.002
89. Yagihashi A, Asanuma K, Tsuji N, Torigoe T, Sato N, Hirata K, Watanabe N (2003) Detection of anti-livin antibody in gastrointestinal cancer patients. Clin Chem 49(7):1206–1208
90. Chen L, Ren GS, Li F, Sun SQ (2008) Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol 14(37):5749–5754
91. Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R, Toma CD (2008) Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol 134(2):237–244. doi:10.1007/s00432-007-0276-z
92. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG (2008) IAP-targeted therapies for cancer. Oncogene 27(48):6252–6275. doi:10.1038/onc.2008.302
93. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54(8):2714–2726. doi:10.1021/jm101505d
94. Wang J, Wang L, Xia B, Yang C, Lai H, Chen X (2013) BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells. PLoS ONE 8(5):e62936. doi:10.1371/journal.pone.0062936
95. Perimenis P, Galaris A, Voulgari A, Prassa M, Pintzas A (2016) IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer 16:624. doi:10.1186/s12885-016-2606-5
96. Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J (2015) The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFalpha-mediated in head and neck squamous cell carcinoma. Radiother Oncol 116(3):495–503. doi:10.1016/j.radonc.2015.05.017
97. Qin Q, Zuo Y, Yang X, Lu J, Zhan L, Xu L, Zhang C, Zhu H, Liu J, Liu Z, Tao G, Dai S, Zhang X, Ma J, Cai J, Sun X (2014) Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol 35(3):2565–2574. doi:10.1007/s13277-013-1338-2
98. Yang C, Wang H, Zhang B, Chen Y, Zhang Y, Sun X, Xiao G, Nan K, Ren H, Qin S (2016) LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. J Exp Clin Cancer Res 35(1):158. doi:10.1186/s13046-016-0435-7
99. Beug ST, LaCasse EC, Korneluk RG (2014) Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncoimmunology 3:e28541. doi:10.4161/onci.28541
100. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ (2012) Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 55(9):4101–4113. doi:10.1021/jm300060k
101. Tchoghandjian A, Souberan A, Tabouret E, Colin C, Denicolai E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D (2016) Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis 7(8):e2325. doi:10.1038/cddis.2016.214
102. Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK (2014) Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 13(4):867–879. doi:10.1158/1535-7163.MCT-13-0798
103. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR (2013) Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res Treat 137(2):359–371. doi:10.1007/s10549-012-2352-6
104. Janzen DM, Tiourin E, Salehi JA, Paik DY, Lu J, Pellegrini M, Memarzadeh S (2015) An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat Commun 6:7956. doi:10.1038/ncomms8956
105. Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, Alexander MD, Kumar PT, Hendi MS, Lee YH, Benetatos CA, Yu G, Kapoor GS, Neiman E, Seipel ME, Burns JM, Graham MA, McKinlay MA, Li X, Wang J, Shi Y, Feltham R, Bettjeman B, Cumming MH, Vince JE, Khan N, Silke J, Day CL, Chunduru SK (2014) Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 57(9):3666–3677. doi:10.1021/jm500176w
106. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M (2013) The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 19(7):1784–1794. doi:10.1158/1078-0432.CCR-12-2518
107. Steinhart L, Belz K, Fulda S (2013) Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 4:e802. doi:10.1038/cddis.2013.320
108. Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T, Fichtner I, Fulda S (2014) Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 124(2):240–250. doi:10.1182/blood-2013-05-500918
109. Brunckhorst MK, Lerner D, Wang S, Yu Q (2012) AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 13(9):804–811. doi:10.4161/cbt.20563
110. Tian A, Wilson GS, Lie S, Wu G, Hu Z, Hebbard L, Duan W, George J, Qiao L (2014) Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Lett 351(2):232–241. doi:10.1016/j.canlet.2014.06.006
111. Eckhardt SG et al (2010) Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 28(no. 15_suppl):2580–2580. doi:10.1200/jco.2010.28.15_suppl.2580
112. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D (2009) X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 284(50):34553–34560. doi:10.1074/jbc.M109.040139
113. Ma JJ, Chen BL, Xin XY (2009) XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 146(2):222–226. doi:10.1016/j.ejogrb.2009.06.011
114. Li QX, Zhao J, Liu JY, Jia LT, Huang HY, Xu YM, Zhang Y, Zhang R, Wang CJ, Yao LB, Chen SY, Yang AG (2006) Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 5(7):860–866
115. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M (2009) Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 27(28):4741–4746. doi:10.1200/JCO.2009.21.8172
116. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M (2011) XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+ 38-cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67–74. doi:10.1007/s10495-010-0545-1
117. Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ (2013) Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol 36(3):239–243. doi:10.1097/COC.0b013e3182467a13
118. Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278(25):23130–23140. doi:10.1074/jbc.M300957200
119. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33–42
120. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406(6798):855–862. doi:10.1038/35022514
121. Guicciardi ME, Mott JL, Bronk SF, Kurita S, Fingas CD, Gores GJ (2011) Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res 317(1):107–116. doi:10.1016/j.yexcr.2010.10.005
122. Welsh K, Milutinovic S, Ardecky RJ, Gonzalez-Lopez M, Ganji SR, Teriete P, Finlay D, Riedl S, Matsuzawa S, Pinilla C, Houghten R, Vuori K, Reed JC, Cosford ND (2016) Characterization of potent SMAC mimetics that sensitize cancer cells to TNF family-induced apoptosis. PLoS ONE 11(9):e0161952. doi:10.1371/journal.pone.0161952
123. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114(8):1117–1127. doi:10.1172/JCI22222
124. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC (2010) IAP regulation of metastasis. Cancer cell 17(1):53–64. doi:10.1016/j.ccr.2009.11.021
125. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG (2007) Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 282(36):26202–26209. doi:10.1074/jbc.M700776200
126. Kanwar JR, Kamalapuram SK, Kanwar RK (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 16(11–12):485–494. doi:10.1016/j.drudis.2011.04.001
127. Ausserlechner MJ, Hagenbuchner J (2016) Mitochondrial survivin: an Achilles’ heel in cancer chemoresistance. Mol Cell Oncol 3(2):e1076589. doi:10.1080/23723556.2015.1076589
128. Yu CC, Wu PJ, Hsu JL, Ho YF, Hsu LC, Chang YJ, Chang HS, Chen IS, Guh JH (2013) Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation. Prostate 73(2):133–145. doi:10.1002/pros.22548
129. Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Liu M, Tomita Y, Pan H, Yoshioka Y, Krajewski K, Roller PP, Wang S (2004) Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 126(51):16686–16687. doi:10.1021/ja047438+
130. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, Miller RS, Yi H, Shangary S, Sun Y, Meagher JL, Stuckey JA, Wang S (2008) SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 68(22):9384–9393. doi:10.1158/0008-5472.CAN-08-2655
131. Hossbach J, Michalsky E, Henklein P, Jaeger M, Daniel PT, Preissner R (2009) Inhibiting the inhibitors: retro-inverso Smac peptides. Peptides 30(12):2374–2379. doi:10.1016/j.peptides.2009.08.001
132. Lau R, Pratt MA (2012) The opposing roles of cellular inhibitor of apoptosis proteins in cancer. ISRN Oncol 2012:928120. doi:10.5402/2012/928120
133. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R (2001) X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 276(29):27058–27063. doi:10.1074/jbc.M102415200
134. Hird AW, Aquila BM, Hennessy EJ, Vasbinder MM, Yang B (2015) Small molecule inhibitor of apoptosis proteins antagonists: a patent review. Expert Opin Ther Pat 25(7):755–774. doi:10.1517/13543776.2015.1041922
135. Chessari G, Buck IM, Day JE, Day PJ, Iqbal A, Johnson CN, Lewis EJ, Martins V, Miller D, Reader M, Rees DC, Rich SJ, Tamanini E, Vitorino M, Ward GA, Williams PA, Williams G, Wilsher NE, Woolford AJ (2015) Fragment-based drug discovery targeting inhibitor of apoptosis proteins: discovery of a non-alanine lead series with dual activity against cIAP1 and XIAP. J Med Chem 58(16):6574–6588. doi:10.1021/acs.jmedchem.5b00706
136. Yang C, Novack DV (2013) Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale. J Bone Miner Metab 31(5):496–506. doi:10.1007/s00774-013-0479-0
137. Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV (2013) Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov 3(2):212–223. doi:10.1158/2159-8290.CD-12-0271
138. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, Stilgenbauer S, Eckhoff SM, Meyer LH, Debatin KM (2016) Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. Cell Death Dis 7:e2052. doi:10.1038/cddis.2015.382
139. Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E (2013) CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 4:e782. doi:10.1038/cddis.2013.305
140. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445–456. doi:10.1016/j.ccr.2007.08.029
141. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P (2011) The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43(3):432–448. doi:10.1016/j.molcel.2011.06.006
142. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, Meier P (2011) Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ 18(8):1376–1386. doi:10.1038/cdd.2011.10
143. Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V (2016) Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget 7(26):39458–39472. doi:10.18632/oncotarget.8462
144. Knights AJ, Fucikova J, Pasam A, Koernig S, Cebon J (2013) Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol Immunother 62(2):321–335. doi:10.1007/s00262-012-1342-1
145. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S, Zobel K, Deshayes K, Vucic D, Jeremias I, Bertrand MJ, Vandenabeele P, Fulda S (2011) Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 13(10):971–979
146. Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, Vucic D, Debatin KM, Fulda S (2013) Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 32(8):988–997. doi:10.1038/onc.2012.108
147. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG (2004) A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305(5689):1471–1474. doi:10.1126/science.1098231
148. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, Oh-Hara T, Tsuruo T (2003) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63(4):831–837
149. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277(46):44236–44243. doi:10.1074/jbc.M207578200
150. Bockbrader KM, Tan M, Sun Y (2005) A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24(49):7381–7388. doi:10.1038/sj.onc.1208888
151. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F (2012) A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS ONE 7(9):e45571. doi:10.1371/journal.pone.0045571
152. Ling X, Li F (2013) An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Trans Res 5(2):139–154
153. Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL (2012) Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol 84(3):268–277. doi:10.1016/j.bcp.2012.04.023
154. West AC, Martin BP, Andrews DA, Hogg SJ, Banerjee A, Grigoriadis G, Johnstone RW, Shortt J (2016) The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis 5:e216. doi:10.1038/oncsis.2016.26
155. Micheau O, Shirley S, Dufour F (2013) Death receptors as targets in cancer. Br J Pharmacol 169(8):1723–1744. doi:10.1111/bph.12238
156. Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628–8633. doi:10.1038/sj.onc.1207232
157. Ozoren N, El-Deiry WS (2002) Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4(6):551–557. doi:10.1038/sj.neo.7900270
158. van Roosmalen IA, Quax WJ, Kruyt FA (2014) Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? Biochem Pharmacol 91(4):447–456. doi:10.1016/j.bcp.2014.08.010
159. Falschlehner C, Schaefer U, Walczak H (2009) Following TRAIL’s path in the immune system. Immunology 127(2):145–154. doi:10.1111/j.1365-2567.2009.03058.x
160. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A (2002) Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8(3):274–281. doi:10.1038/nm0302-274
161. Parrish AB, Freel CD, Kornbluth S (2013) Cellular mechanisms controlling caspase activation and function. Cold Spring Harbor Perspect Biol. doi:10.1101/cshperspect.a008672
162. Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, Xu L (2009) A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 9:392. doi:10.1186/1471-2407-9-392
163. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC (2004) Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23(49):8105–8117. doi:10.1038/sj.onc.1207967
164. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK (2006) Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 5(11):2737–2746. doi:10.1158/1535-7163.MCT-06-0426
165. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T (2009) XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460(7258):1035–1039. doi:10.1038/nature08229
166. Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA (2006) Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 5(7):1844–1853. doi:10.1158/1535-7163.MCT-06-0050
167. Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM (2004) Mutation analysis of the apoptotic “death-receptors” and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int JCancer 109(5):661–667. doi:10.1002/ijc.20008
168. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26(19):7046–7055. doi:10.1128/MCB.00520-06
169. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63(17):5390–5400
170. Timur M, Cort A, Ozdemir E, Sarikcioglu SB, Sanlioglu S, Sanlioglu AD, Ozben T (2015) Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors. Anticancer Agents Med Chem 15(1):99–106
171. Venza I, Visalli M, Oteri R, Teti D, Venza M (2014) Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol 21(2):439–446. doi:10.1016/j.intimp.2014.05.024
172. Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM (2016) The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAILinduced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. Int J Oncol 49(1):74–88. doi:10.3892/ijo.2016.3518
173. Son JK, Varadarajan S, Bratton SB (2010) TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ 17(8):1288–1301. doi:10.1038/cdd.2010.9
174. Subramanian A, Andronache A, Li YC, Wade M (2016) Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA. Oncotarget 7(13):15986–16002. doi:10.18632/oncotarget.7558
175. Gupta SC, Reuter S, Phromnoi K, Park B, Hema PS, Nair M, Aggarwal BB (2011) Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem 286(2):1134–1146. doi:10.1074/jbc.M110.191379
176. Babykutty S, S PP, J NR, Kumar MA, Nair MS, Srinivas P, Gopala S (2012) Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-kappaB in colon cancer cells. Mol Carcinog 51(6):475–490. doi:10.1002/mc.20812
177. Gillissen B, Wendt J, Richter A, Richter A, Muer A, Overkamp T, Gebhardt N, Preissner R, Belka C, Dorken B, Daniel PT (2010) Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 188(6):851–862. doi:10.1083/jcb.200912070
178. Ortiz-Ferron G, Yerbes R, Eramo A, Lopez-Perez AI, De Maria R, Lopez-Rivas A (2008) Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 18(6):664–676. doi:10.1038/cr.2008.54
179. Rosato RR, Almenara JA, Coe S, Grant S (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67(19):9490–9500. doi:10.1158/0008-5472.CAN-07-0598
180. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389–399. doi:10.1016/j.ccr.2006.08.027
181. Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT (2013) Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode. Cell Death Dis 4:e643. doi:10.1038/cddis.2013.67
182. Huang Y, Yang X, Xu T, Kong Q, Zhang Y, Shen Y, Wei Y, Wang G, Chang KJ (2016) Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int J Oncol 49(1):153–163. doi:10.3892/ijo.2016.3525
183. Morizot A, Merino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O (2011) Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 18(4):700–711. doi:10.1038/cdd.2010.144
184. Seo OW, Kim JH, Lee KS, Lee KS, Kim JH, Won MH, Ha KS, Kwon YG, Kim YM (2012) Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-kappaB-dependent cFLIP expression in HeLa cells. Exp Mol Med 44(11):653–664. doi:10.3858/emm.2012.44.11.074
185. Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, Cao L (2011) Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res 17(10):3181–3192. doi:10.1158/1078-0432.CCR-10-2874
186. Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A (2014) Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPs). Anticancer Res 34(12):7007–7020
187. Obexer P, Ausserlechner MJ (2014) X-linked inhibitor of apoptosis protein: a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol 4:197. doi:10.3389/fonc.2014.00197
188. Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O’Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM (2016) Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122(4):588–597. doi:10.1002/cncr.29783